Thursday, June 22, 2023
PharmaLogic and UPMC (University of Pittsburgh Medical Center) have entered into a non-exclusive agreement aimed at translating investigational radiopharmaceuticals into clinically relevant drugs for the diagnosis and treatment of cancer, cardiovascular diseases, and other medical conditions. The partnership intends to provide patients and clinicians in the communities surrounding UPMC with access to novel diagnostic and therapeutic agents that are currently not available.
Under the agreement, PharmaLogic will manage and co-fund the establishment of a world-class Current Good Manufacturing Practice (cGMP) facility on the UPMC campus in Pittsburgh's Oakland neighborhood. PharmaLogic, as an experienced contract development and manufacturing organization, brings the necessary expertise to build and operate a successful radiopharmaceutical production facility. UPMC, on the other hand, will serve as the anchor clinical customer and provide strategic, research, and operational support. The market for radiopharmaceuticals is projected to grow at a rapid pace, and UPMC's involvement will ensure its prominent position in this field.
Alfred L'Altrelli, Pharm.D., senior director of pharmacy at UPMC, expressed excitement about the partnership, emphasizing that it will enable the production of cutting-edge therapies that were previously unavailable locally. In addition to benefiting patients, the collaboration is expected to transform UPMC's clinical research infrastructure, enabling the discovery of new molecules and facilitating their development through all research and development phases.
Scott Holbrook, chief strategy officer and general manager for PharmaLogic, expressed gratitude for the opportunity to partner with UPMC, recognizing the significance of this collaboration for their organization. He believes that the facility established through this partnership will serve as a global center of excellence in the field.
Timothy R. Billiar, M.D., UPMC's executive vice president and chief scientific officer, reaffirmed UPMC's commitment to providing high-quality and affordable care to patients and communities. By collaborating with PharmaLogic, UPMC aims to offer patients the latest therapeutic options in areas with significant clinical needs. UPMC will continue to work with the University of Pittsburgh and receive support from UPMC Enterprises to remain at the forefront of medical advancements.
This agreement between PharmaLogic and UPMC signifies their joint effort to advance the development and availability of innovative radiopharmaceuticals, benefiting patients, clinicians, and the community as a whole.
